Trial Profile
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jan 2014
Price :
$35
*
At a glance
- Drugs Toreforant (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 03 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
- 13 Jun 2013 New trial record